Research & Education

Novel Agents and biomarker driven therapies for personalized treatment of advanced NSCLC

Implications of the new IASLC staging system and adenocarcinoma classification for systemic treatment of NSCLC - Eric Lim, MB, ChB, MD, MSc, FRCS (C-Th)
Molecular profiling and personalized medicine for patients with lung cancer - David Gandara, MD
The relevance of histological diagnosis in making treatment decisions - Giorgio Scagliotti, MD
Making NSCLC a chronic disease: reality or dream? - Tony Mok, MD
New targets for lung cancer - Suresh Ramalingam, MD